10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	MINARIK Jiri SANDECKÁ Viera MAISNAR Vladimír GREGORA Evzen SPICKA Ivan STAROSTKA David PLONKOVÁ Hana JARKOVSKÝ Jiří WALTEROVA Lenka WROBEL Marek ADAMOVÁ Dagmar PIKA Tomas MELICHAROVÁ Hana POUR Ludek RADOCHA Jakub PAVLICEK Petr STRAUB Jan GUMULEC Jaromir BAČOVSKÝ Jaroslav ADAM Zdeněk SCUDLA Vlastimil HAJEK Roman
Year of publication	2013
Type	Article in Periodical
Magazine / Source	Leukemia Research
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1016/j.leukres.2013.06.019
Field	Oncology and hematology
Keywords	Multiple myeloma; Thalidomide; Response rate; Prognostic factors; Combined regimens; Adverse events
Description	We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
Related projects:	From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies